Zentalis Pharmaceuticals (ZNTL) Insider Trading & Ownership $1.23 -0.03 (-2.00%) Closing price 05/7/2025 03:59 PM EasternExtended Trading$1.24 +0.02 (+1.55%) As of 05/7/2025 06:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Zentalis Pharmaceuticals (NASDAQ:ZNTL) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage3.60%Number OfInsiders Buying(Last 12 Months)3Amount OfInsider Buying(Last 12 Months)$178,200.00Number OfInsiders Selling(Last 12 Months)4Amount OfInsider Selling(Last 12 Months)$180,656.29 Get ZNTL Insider Trade Alerts Want to know when executives and insiders are buying or selling Zentalis Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address ZNTL Insider Buying and Selling by Quarter Zentalis Pharmaceuticals Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails4/30/2025Scott Dunseth MyersDirectorBuy21,000$1.40$29,400.00 2/6/2025Ingmar BrunsInsiderBuy20,000$2.28$45,600.00 2/3/2025Vincent VultaggioInsiderSell2,615$1.71$4,471.65 1/31/2025Jan SkvarkaDirectorBuy60,000$1.72$103,200.00 1/2/2025Mark LacknerInsiderSell4,411$3.12$13,762.32 10/4/2024Vincent VultaggioInsiderSell1,603$3.18$5,097.54 5/31/2024Cam GallagherCFOSell9,597$11.98$114,972.06 5/9/2024Diana HausmanInsiderSell3,356$12.62$42,352.72 (Data available from 1/1/2013 forward) ZNTL Insider Trading Activity - Frequently Asked Questions Who is on Zentalis Pharmaceuticals's Insider Roster? The list of insiders at Zentalis Pharmaceuticals includes Cam Gallagher, Carrie Brownstein, David Michael Johnson, Diana Hausman, Ingmar Bruns, Jan Skvarka, Kevin D Bunker, Kimberly Blackwell, Mark Lackner, Matrix Capital Management Comp, Melissa B Epperly, Scott Dunseth Myers, and Vincent Vultaggio. Learn more on insiders at ZNTL. What percentage of Zentalis Pharmaceuticals stock is owned by insiders? 3.60% of Zentalis Pharmaceuticals stock is owned by insiders. Learn more on ZNTL's insider holdings. Which Zentalis Pharmaceuticals insiders have been buying company stock? The following insiders have purchased ZNTL shares in the last 24 months: David Michael Johnson ($167,960.00), Ingmar Bruns ($45,600.00), Jan Skvarka ($103,200.00), Kimberly Blackwell ($51,450.00), Matrix Capital Management Comp ($107,861,600.00), and Scott Dunseth Myers ($29,400.00). How much insider buying is happening at Zentalis Pharmaceuticals? Insiders have purchased a total of 4,883,000 ZNTL shares in the last 24 months for a total of $108,259,210.00 bought. Which Zentalis Pharmaceuticals insiders have been selling company stock? The following insiders have sold ZNTL shares in the last 24 months: Cam Gallagher ($857,856.54), Carrie Brownstein ($207,246.00), Diana Hausman ($42,352.72), Jan Skvarka ($125,250.00), Kevin D Bunker ($2,401,600.00), Mark Lackner ($13,762.32), Melissa B Epperly ($136,334.12), and Vincent Vultaggio ($9,569.19). How much insider selling is happening at Zentalis Pharmaceuticals? Insiders have sold a total of 154,206 Zentalis Pharmaceuticals shares in the last 24 months for a total of $3,793,970.89 sold. Zentalis Pharmaceuticals Key ExecutivesDr. Kimberly Lynn Blackwell M.D. (Age 55)CEO & Director Compensation: $1.17MMr. Cameron S. Gallagher M.B.A. (Age 54)Co-Founder, President, Interim CFO, Interim Treasurer & Director Compensation: $892.15kMs. Andrea Paul J.D. (Age 43)Chief Legal Officer & Corporate Secretary Compensation: $682.47kDr. Diana F. Hausman M.D. (Age 61)Chief Medical Officer & Director Compensation: $38.44kMr. Vincent Vultaggio (Age 41)VP of Finance & Interim Principal Accounting Officer 1 recent tradesDr. Mark Lackner Ph.D. (Age 56)Chief Scientific Officer Ms. Kimberly FreemanChief Strategy OfficerDr. Kyle Rasbach Ph.D. (Age 44)Pharm.D., Chief Business Officer Dr. Adrian Jubb M.D.Ph.D., Executive Vice President of Clinical Development More Insider Trading Tools from MarketBeat Related Companies ERAS Insider Trading SANA Insider Trading ZVRA Insider Trading ALT Insider Trading ORKA Insider Trading RVNC Insider Trading TECX Insider Trading TSHA Insider Trading ORIC Insider Trading CMPS Insider Trading Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles The Top-Ranked Insider Buys From April by Market CapMcDonald’s Insiders Sell Shares! Investors Should Do the Opposite5 Mid-Cap Stocks Insiders Are Buying This YearInsider Buying in This Stock Reiterates Analysts Bullish OutlookBeware of BigBear.ai: Insiders Are Selling—Should You? This page (NASDAQ:ZNTL) was last updated on 5/8/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredTrump to redistribute trillions of dollars Seeing how the media and other analysts are covering Trump’s actions – it’s laughable. At least it would be la...Porter & Company | Sponsored270x more lucrative than NVIDIA???270x more lucrative than NVIDIA??? If you've missed out on NVIDIA's recent 1,600% run... Don't worry. ...Behind the Markets | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredVanishing BenefitsWhat would you do if your next Social Security check simply never arrived? If you called and the line was d...Investors Alley | SponsoredSilver’s 332% Surge?Silver has quietly become one of the most promising investments of this cycle. Russia is now stockpiling silve...Lear Capital | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zentalis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zentalis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
